Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma
Soft Tissue Sarcoma
About this trial
This is an interventional treatment trial for Soft Tissue Sarcoma focused on measuring soft tissue sarcoma, preoperative radiotherapy, moderately fractionated RT, Complications, PARP inhibitor
Eligibility Criteria
Inclusion Criteria: Age older than 18 years. Histology proven soft tissue sarcoma of truncal or extremity, deemed appropriate for preoperative radiotherapy and conservative surgery by multidisciplinary discussion. ECOG 0-3 Histology reviewed by reference pathologist Lesion can be assessed Can tolerate radiotherapy and Fluzoparib (Fluzoparib group) Agree contraception. Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed Exclusion Criteria: No gross tumor post-resection in other center. Contraindications to Fluzoparib, including allergic to Fluzoparib, active bleeding, ulcer, enteric perforation, enteric obstruction, uncontrolled hypertension, Grade 3 to 4 cardiac insufficiency (per NYHA criteria), and severe hepatic or renal insufficiency (Grade 4), etc. Dermatofibrosarcoma protuberans(DFSP), Desmoids, etc. Benign histology Secondary cancer within 5 years (except cervical carcinoma in situ or early-stage skin basal cell carcinoma) STS can be cured by extensive operation alone. Previous irradiation to the same area radiological evidence of distant metastases Other contraindications, can't tolerate operation or other treatment needed in this study.
Sites / Locations
- Beijing Jishuitan HospitalRecruiting
- Cancer Hospital and Institute, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Preoperative moderately fractionated RT with Fluzoparib
Preoperative moderately fractionated RT without Fluzoparib
Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr). One week before RT onset, during radiotherapy and 5 weeks post-RT, patients also take oral Fluzoparib (100mg, BID, five days per week). Wide resection surgery would be done around 6 -10 weeks post-RT.
Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr). No radio-sensitizing drugs was given. Wide resection surgery would be done around 6 -10 weeks post-RT.